Contemporary Section 2 topline effects display NS002’s doable for best-in-class epinephrine supply, with statistically vital enhancements in early absorption in comparison to EpiPen®; pivotal learn about deliberate for This autumn 2026
Corporate advancing pipeline property NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) towards first-in-human research anticipated to begin in the second one part of 2026, considerably increasing the Corporate’s intranasal product portfolio into further prime worth healing spaces
Corporate neatly funded via deliberate NS002 pivotal learn about and doable NDA submission
TEL AVIV, Israel, March 25, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical corporate centered at the building of cutting edge intranasal merchandise, lately introduced the submitting of its annual record on Shape 20-F for the yr ended December 31, 2025, and supplied a industry replace highlighting fresh Section 2 effects for NS002 and upcoming scientific milestones.
Industry Replace
NS002 – Intranasal powder Epinephrine for Anaphylaxis
Finished Section 2 unmarried and repeat dose scientific learn about, with topline effects demonstrating statistically vital enhancements in time to healing threshold (T100) and the next share of contributors attaining healing epinephrine ranges inside the first mins following management, in comparison to EpiPen®. The knowledge additionally demonstrated NS002’s constant absorption throughout real-world prerequisites, together with below a nasal allergic problem designed to simulate anaphylaxis situations. Advancing towards pivotal building, with a pivotal scientific learn about anticipated to begin within the fourth quarter of 2026 and a deliberate readout within the first quarter of 2027, matter to regulatory alignment. The Corporate believes the sure Section 2 effects enhance persevered building towards a possible NDA submission.
Early Pipeline
Nasus is advancing its earlier-stage pipeline techniques, which leverage the Corporate’s proprietary intranasal powder platform:
NS003 – Ondansetron for chemotherapy-induced nausea and vomitingNS004 – focused on metabolic disordersNS005 – focused on cardiovascular sicknesses
All techniques are recently in preclinical building, with first-in-human Section 1 research anticipated to begin in the second one part of 2026 for NS003 and NS004, supporting the ongoing growth of the Corporate’s intranasal product portfolio.
Monetary Effects
Analysis and Construction Bills: Analysis and building bills have been $2.4 million for the yr ended December 31, 2025, in comparison with $0.3 million for the yr ended December 31, 2024. The rise was once basically as a result of bills paid in reference to the advance of NS002.
Basic and Administrative Bills: Basic and administrative bills have been $2.7 million for the yr ended December 31, 2025, in comparison with $0.7 million for the yr ended December 31, 2024. The rise was once principally because of the corporate’s transition to a public corporate.
Web Loss: For the yr ended December 31, 2025, internet loss was once $5.9 million in comparison with a internet lack of $1.5 million for the yr ended December 31, 2024. The overall collection of stocks remarkable as of December 31, 2025 was once 9,015,383.
About Nasus PharmaNasus Pharma is a clinical-stage pharmaceutical corporate growing various intranasal powder merchandise addressing acute scientific prerequisites in the neighborhood. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being advanced as a needle-free selection to Epinephrine autoinjectors for sufferers with anaphylaxis. Intranasal management is most fitted for the ones eventualities by which speedy drug supply is needed and gives needle-free, easy-to-use possible choices. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) era is designed for speedy and dependable drug supply, leveraging the nasal hollow space’s wealthy vascular community for speedy absorption. The PBI formula makes use of uniform round powder debris for large dispersion and probably quicker, upper absorption in comparison to liquid-based nasal merchandise. For additional details about the Corporate, please discuss with www.nasuspharma.com or apply on Twitter (X) or LinkedIn.
Ahead Taking a look StatementsThis press liberate incorporates “forward-looking statements” inside the which means of the Personal Securities Litigation Reform Act of 1995 and different U.S. federal securities regulations. Phrases similar to “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the destructive of those phrases, an identical expressions or diversifications of such phrases are meant to spot forward-looking statements. As an example, Nasus Pharma is the usage of ahead searching statements on this press liberate when it discusses: the timing and result of deliberate scientific research, together with the NS002 pivotal learn about, doable regulatory submissions, together with a possible NDA, the advance and timing of pipeline techniques, together with NS003, NS004 and NS005, anticipated scientific and building milestones, growth of the Corporate’s product portfolio, and the Corporate’s monetary place and anticipated money runway. Historic result of clinical analysis and scientific and preclinical trials don’t be sure that the conclusions of long term analysis or trials will counsel equivalent and even an identical conclusions. Ahead-looking statements are in response to the Corporate’s present expectancies and are matter to uncertainties, dangers and assumptions which can be tricky to are expecting. Additional, sure forward-looking statements are in response to assumptions as to long term occasions that would possibly not end up to be correct. Those and different dangers and uncertainties are described extra absolutely within the phase titled “Risk Factors” within the Corporate’s Annual Document on Shape 20-F filed with the U.S. Securities and Alternate Fee on March 25, 2026. Ahead-looking statements contained on this press liberate are made as of this date, and the Corporate undertakes no accountability to replace such data apart from as required below acceptable regulation.
